Trailing-twelve-month (TTM) revenue is $730.02 Million with a year-over-year growth of +1.35%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $191,840,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-06 |
| Q4 FY2025Period ended 2025-12-31 | $183,105,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-26 |
| Q1 FY2026Period ended 2026-03-31 | $171,171,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-07 |
| Q2 FY2026Period ended 2026-06-30 | $183,903,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-06 |
| TTM revenue | $730,019,000 |
Current P/S: $1,118,637,355 market capitalization ÷ $730,019,000 TTM revenue = 1.53x.
Market capitalization source: FMP quote. Quote observed 2026-10-05T20:00:02.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $183.90M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T12:50:27.500Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Active Pharmaceutical Ingredient Segment | $18M | $18M | N/A | N/A | N/A | N/A |
| Epinephrine | N/A | N/A |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| C | $3M | N/A | N/A | N/A | N/A | N/A |
| China | N/A | N/A |
$730.02M
$730.02 Million
+1.35%
vs. $720.30M a year ago (TTM)
+13.71%
5 Year compound annual growth rate
1 Year
+1.35%
3 Year
+10.51%
5 Year
+13.71%
10 Year
+10.53%
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $719.89M | ($12.08M) | (1.65%) |
| 2024 | $731.97M | +$87.57M | +13.59% |
| 2023 | $644.39M | +$145.41M | +29.14% |
| 2022 | $498.99M | +$61.22M | +13.98% |
| 2021 | $437.77M | +$87.92M | +25.13% |
| 2020 |
TTM Growth
+1.35%
3-Year CAGR
+10.51%
5-Year CAGR
+13.71%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T12:50:27.500Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| N/A |
| N/A |
| N/A |
| $71M |
| Finished Pharmaceutical Products Segment | N/A | $420M | N/A | N/A | N/A | N/A |
|---|
| Other | N/A | N/A | N/A | N/A | $19M | N/A |
|---|
| Other revenues | N/A | N/A | N/A | $51M | N/A | N/A |
|---|
| Product | N/A | N/A | N/A | N/A | $713M | N/A |
|---|
| Product revenues, net | N/A | N/A | N/A | $593M | N/A | N/A |
|---|
| Research and development services | N/A | N/A | $4M | N/A | N/A | N/A |
|---|
| N/A |
| N/A |
| $3M |
| CHINA | N/A | $6M | $5M | $5M | $4M | N/A |
|---|
| France | N/A | N/A | N/A | N/A | N/A | $35M |
|---|
| FRANCE | N/A | $12M | $7M | $5M | $20M | N/A |
|---|
| U | $333M | N/A | N/A | N/A | N/A | N/A |
|---|
| UNITED STATES | N/A | $420M | $487M | $635M | $708M | $681M |
|---|
| $349.85M |
| +$27.49M |
| +8.53% |
| 2019 | $322.36M | +$27.69M | +9.40% |
| 2018 | $294.67M | +$54.49M | +22.69% |
| 2017 | $240.18M | ($14.99M) | (5.87%) |
| 2016 | $255.16M | +$3.65M | +1.45% |
